Mortaja Mahsa, Adams Stephen R, McKay Rana R, Gutkind J Silvio, Advani Sunil J
Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, 92093, USA.
Department of Pharmacology, University of California San Diego, La Jolla, CA, 92093, USA.
NPJ Precis Oncol. 2025 Apr 4;9(1):97. doi: 10.1038/s41698-025-00885-x.
Concurrent chemo-radiotherapy is standard of care for locally advanced cancer patients. While radiotherapy and immuno-oncology have advanced precision oncology, chemotherapies in the chemo-radiotherapy paradigm remain non-targeted cytotoxins. Antibody drug conjugates offer an opportunity for targeted radiosensitization that stimulates immune responses while protecting normal tissues. Here, we discuss the rationale for combining antibody drug conjugates, radiotherapy and immunotherapies and opportunities for clinical translation to advance towards targeted chemo-radio-immunotherapy precision cancer care.
同步放化疗是局部晚期癌症患者的标准治疗方法。虽然放射治疗和免疫肿瘤学在精准肿瘤学方面取得了进展，但放化疗模式中的化疗药物仍然是非靶向细胞毒素。抗体药物偶联物为靶向放射增敏提供了机会，既能刺激免疫反应，又能保护正常组织。在此，我们讨论将抗体药物偶联物、放射治疗和免疫治疗相结合的基本原理，以及临床转化的机会，以推动靶向化放疗-免疫治疗精准癌症护理的发展。
Zotero 插件
